Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Wellbeing Digital Sciences Inc (OP: KONEF ) N/A UNCHANGED Last Price Updated: 3:57 PM EST, Mar 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Wellbeing Digital Sciences Inc < Previous 1 2 3 Next > World's Largest Psychedelics Conference Sheds Light On Alternative Mental Health Therapies, Boasts 12K Attendees June 26, 2023 The Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored a Psychedelic Science conference in Denver last week, which gathered over 12,000 people from the entire psy Via Benzinga Wellbeing Digital Subsidiary KGK Science to Participate at the Mushroom Summit and Psychedelic Science Conference June 19, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire Wellbeing Digital Enters into Share Purchase Agreement with Cardinal Group June 16, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire Wellbeing Digital Subsidiary KGK Science to Participate at the Nutrition Industry Association Spring Conference May 25, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire Wellbeing Subsidiary KGK Science Announces Successful Results of UP360, a Nutraceutical Ingredient Demonstrating Beneficial Immune Defense Response May 03, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial April 18, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire Wellbeing Subsidiary KGK Science Receives Institutional Review Board Approval April 11, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire Wellbeing Announces Cease Trade Order April 06, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire Wellbeing Provides Bi-Weekly Default Status Report March 16, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire Wellbeing Digital to Participate at the Benzinga Psychedelic Capital Conference March 16, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More March 13, 2023 Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial Via Benzinga Wellbeing Digital to Participate at the Cantor Fitzgerald Virtual Panel Discussion March 13, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire Another Company Approved To Begin Production Of Psychedelics Under Canadian Dealers License March 09, 2023 A Contract Research Organization (CRO) and a wholly-owned subsidiary of Wellbeing Digital Sciences Inc. Via Benzinga Wellbeing Digital to Participate in The Global Biomedical Design Conference March 09, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person March 08, 2023 This year’s edition of the Benzinga Psychedelics Capital Conference, THE place to be for those interested or already involved in the space, will take place on April 13, following our established... Via Benzinga Wellbeing Subsidiary KGK Science Applies for a Controlled Substances Dealers License and Receives Approval to Proceed with Buildout March 08, 2023 From WELLBEING DIGITAL SCIENCES Via Business Wire Wellbeing Provides Bi-Weekly Default Status Report March 02, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire Wellbeing Digital to Participate in MarigoldLIVE: International Women’s Day Networking Event March 01, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More February 21, 2023 Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... Via Benzinga Wellbeing Provides Bi-Weekly Default Status Report February 16, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire Wellbeing Subsidiary KGK Science Announces Publication of Safety Studies on Paraxanthine and Comparison to Caffeine Toxicity. February 15, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder February 14, 2023 Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a... Via Benzinga Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial February 14, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire Wellbeing Announces Delay in Filing Its Financial Statements and Management Cease Trade Order February 01, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire Women's Footprint In Psychedelics Is Undeniable, Benzinga's Psychedelics Advisory Council's Six New Trailblazers January 30, 2023 In its capacity as a financial news and media outlet, Benzinga has added six new members to its Psychedelics Advisory Council. Via Benzinga Wellbeing Digital to Participate in the Psychedelic Medicine Association Webinar January 25, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire Wellbeing Digital Announces Change of Auditor January 18, 2023 From Wellbeing Digital Sciences Inc. Via Business Wire First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval December 27, 2022 The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a... Via Benzinga Wellbeing Subsidiary KGK Science Receives Approval for First-of-its-Kind Psylocibin Clinical Trial December 22, 2022 From Wellbeing Digital Sciences Inc. Via Business Wire Wellbeing Subsidiary KGK Science Awarded Cannabis Research License from Health Canada December 08, 2022 From Wellbeing Digital Sciences Inc. Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.